Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.
Ryan Nolan, PharmD Candidate 2021
Advertisement
Articles by Ryan Nolan, PharmD Candidate 2021
On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).
Advertisement
Latest Updated Articles
Belantamab mafodotin-blmf for Relapsed or Refractory Multiple MyelomaPublished: February 12th 2021 | Updated:
Remdesivir in the Treatment of COVID-19Published: January 14th 2021 | Updated:
Advertisement
Advertisement
